Llewelyn Engel
Llewelyn Engel focuses her practice on government investigations, government contracts and public policy matters. Llewelyn has successfully represented clients in high-profile investigations by the Department of Justice and Congress that entail significant legal, political and reputational risks. Llewelyn is experienced in navigating the political vetting process and has helped a high-profile client nominated by the President undergo the confirmation process.
BIOSECURE Act: US to Target Chinese Biotechnology Companies
By Sabine Naugès and Llewelyn Engel on Sep 26, 2024
Posted In Compliance, Foreign Investment
On September 9, the US House of Representatives passed H.R. 8333, known as the BIOSECURE Act, targeting WuXi AppTec, BGI, MGI, Complete Genomics, WuXi Biologics and Chinese biotechnology companies more broadly. Measures & Context If signed into law, the BIOSECURE Act would prohibit entities that receive US federal funding from doing business with foreign biotechnology...
Continue Reading
